LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA)

• UNSPSC Description:

  LSKL, Inhibitor of Thrombospondin (TSP-1) TFA is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) TFA can readily crosse the blood-brain barrier[1][2].

• Target Antigen:

  TGF-β Receptor

• Type:

  Peptides

• Related Pathways:

  TGF-beta/Smad

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/lskl-inhibitor-of-thrombospondin-tsp-1-tfa.html

• Purity:

  99.30

• Solubility:

  DMSO : 250 mg/mL (ultrasonic)|H2O : 100 mg/mL (ultrasonic)

• Smiles:

  CC(C)C[C@@H](C(N)=O)NC([C@H](CCCCN)NC([C@H](CO)NC([C@H](CC(C)C)N)=O)=O)=O.O=C(O)C(F)(F)F

• Molecular Weight:

  572.62

• References & Citations:

  [1]Liao F, et al. LSKL peptide alleviates subarachnoid fibrosis and hydrocephalus by inhibiting TSP1-mediated TGF-β1 signaling activity following subarachnoid hemorrhage in rats. Exp Ther Med. 2016 Oct;12(4):2537-2543. Epub 2016 Aug 31.|[2]Laurent MA, et al. In silico characterization of the interaction between LSKL peptide, a LAP-TGF-beta derived peptide, and ADAMTS1. Comput Biol Chem. 2016 Apr;61:155-61.|[3]Kuroki H, et al. Effect of LSKL peptide on thrombospondin 1-mediated transforming growth factor β signal activation and liver regeneration after hepatectomy in an experimental model. Br J Surg. 2015 Jun;102(7):813-25.Cell Death Dis. 2022 Jul 30;13(7):663.|Front Cell Dev Biol. 18 February 2021.|Front Immunol. 2022 Mar 18;13:853894.|J Am Heart Assoc. 2021 Oct 8;e022701.|J Exp Clin Cancer Res. 2022 Aug 26;41(1):259.|Ann Transl Med. 2021 Dec;9(23):1738.|Antioxidants (Basel). 2023 Nov 21, 12(12), 2024.|Cancer Sci. 2024 Jun 28.|Cancers. 2019 Dec 5;11(12):1946.|Cell Tissue Res. 2022 Mar 9.|Environ Pollut. 2020 Apr;259:113915.|PLoS One. 2024 Oct 7;19(10):e0311594.|Sci China Life Sci. 2024 Oct 12.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Clinical Information:

  No Development Reported

• CAS Number:

  2828433-17-4